JP7500555B2 - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents
ヒト免疫不全ウイルス複製の阻害剤 Download PDFInfo
- Publication number
- JP7500555B2 JP7500555B2 JP2021521995A JP2021521995A JP7500555B2 JP 7500555 B2 JP7500555 B2 JP 7500555B2 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP 7500555 B2 JP7500555 B2 JP 7500555B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- indazol
- ethyl
- mmol
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750395P | 2018-10-25 | 2018-10-25 | |
| US62/750,395 | 2018-10-25 | ||
| PCT/IB2019/059004 WO2020084480A1 (en) | 2018-10-25 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022505597A JP2022505597A (ja) | 2022-01-14 |
| JPWO2020084480A5 JPWO2020084480A5 (https=) | 2022-10-11 |
| JP2022505597A5 JP2022505597A5 (https=) | 2022-10-11 |
| JP7500555B2 true JP7500555B2 (ja) | 2024-06-17 |
Family
ID=68344929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521995A Active JP7500555B2 (ja) | 2018-10-25 | 2019-10-22 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210393633A1 (https=) |
| EP (1) | EP3870575B1 (https=) |
| JP (1) | JP7500555B2 (https=) |
| ES (1) | ES2942998T3 (https=) |
| PT (1) | PT3870575T (https=) |
| WO (1) | WO2020084480A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019198024A1 (en) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| US20210395262A1 (en) * | 2018-10-24 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| EP3962603A1 (en) * | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| KR20220066922A (ko) * | 2019-09-20 | 2022-05-24 | 아이디어야 바이오사이언시스 인코포레이티드 | Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016504392A (ja) | 2013-01-09 | 2016-02-12 | ギリアード サイエンシーズ， インコーポレイテッド | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 |
| JP2016510038A (ja) | 2013-03-01 | 2016-04-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のためのアミド化合物 |
| JP2017525722A (ja) | 2014-08-29 | 2017-09-07 | ギリアード サイエンシーズ， インコーポレイテッド | 抗レトロウイルス剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| US20210379071A1 (en) * | 2018-11-05 | 2021-12-09 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
-
2019
- 2019-10-22 US US17/284,855 patent/US20210393633A1/en not_active Abandoned
- 2019-10-22 WO PCT/IB2019/059004 patent/WO2020084480A1/en not_active Ceased
- 2019-10-22 PT PT197946791T patent/PT3870575T/pt unknown
- 2019-10-22 JP JP2021521995A patent/JP7500555B2/ja active Active
- 2019-10-22 EP EP19794679.1A patent/EP3870575B1/en active Active
- 2019-10-22 ES ES19794679T patent/ES2942998T3/es active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016504392A (ja) | 2013-01-09 | 2016-02-12 | ギリアード サイエンシーズ， インコーポレイテッド | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 |
| JP2016510038A (ja) | 2013-03-01 | 2016-04-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のためのアミド化合物 |
| JP2017525722A (ja) | 2014-08-29 | 2017-09-07 | ギリアード サイエンシーズ， インコーポレイテッド | 抗レトロウイルス剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210393633A1 (en) | 2021-12-23 |
| WO2020084480A1 (en) | 2020-04-30 |
| EP3870575A1 (en) | 2021-09-01 |
| EP3870575B1 (en) | 2023-03-29 |
| JP2022505597A (ja) | 2022-01-14 |
| PT3870575T (pt) | 2023-05-12 |
| ES2942998T3 (es) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7500555B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7526174B2 (ja) | キナゾリニル－インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用 | |
| JP7532354B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7433303B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7398448B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7361766B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| US20240374598A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| TW201906834A (zh) | 人類免疫不全病毒複製之抑制劑 | |
| JP2021521131A (ja) | ヒト免疫不全ウイルス複製の阻害剤としての４−オキソ−３，４−ジヒドロキナゾリン化合物 | |
| JP2022509919A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP7545414B2 (ja) | ヒト免疫不全ウイルス複製阻害剤 | |
| CN115397424A (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| TW202128648A (zh) | 人類免疫不全病毒複製之抑制劑 | |
| CN116323585A (zh) | 新化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220928 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240409 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240605 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7500555 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |